Efficacy and Safety of Empagliflozin as Add-On Therapy in Patients of Type-2 Diabetes Mellitus by Wazir, Nauman & Rehman, Shafqat Ur







EFFICACY AND SAFETY OF EMPAGLIFLOZIN AS ADD  ON THERAPY IN 
PATIENTS OF TYPE 2 DIABETES MELLITUS 
 
Nauman Wazir1, Shafqat Ur Rehman2 
ABSTRACT: 
OBJECTIVES:  
To assess efficacy of two doses i.e., 10 mg and 25 mg in lowering the glycated haemoglobin (HbA1C) and 
fasting blood glucose (FBG) in patients of type 2 diabetes mellitus (T2DM) having suboptimal glycaemic 
control on maximal doses of Metformin and Sitagliptin, and to see the frequency of its side-effects. 
METHODOLOGY: 
The study design was a randomized control trial. Fifty nine adult patients of T2DM who were already on 2000 
mg of Metformin and 100 mg of Sitagliptin and were having suboptimal glycaemic control (HBA1C >7% and 
<12%) were randomized to two groups, one group receiving 10 mg (Group A) and the other group receiving 25 
mg of empagliflozin (Group B) as an additional treatment. HbA1C and FBG were taken before and 12 weeks 
after addition of empagliflozin in both the groups. Side effects of empagliflozin such as urinary tract infections 
(UTI) and genital mycotic infections were also recorded in both the groups. 
RESULTS: 
Total patients in-group A were 31 and their mean age was 51.48±4.29 years. In-group B there were 28 patients 
and their mean age was 52.39±5.20 years. There was a statistically significant reduction of both HbA1C and 
FBG in both the groups after empagliflozin treatment; (p=0.000) for both HbA1C and FBG in both the groups. 
Although numerically UTI and genital mycotic infections were more than pre-treatment numbers, they were not 
statistically significant (p>0.05). 
CONCLUSION: 
Empagliflozin can be safely added to the oral anti-diabetic regimen of patients with type 2 diabetes mellitus 
who have suboptimal glycaemic control and results in significant improvement in HbA1C. 




Metformin is advocated and used as first-line 
treatment to attain glycaemic control in patients with 
T2DM. However, metformin monotherapy may 




a long time1, and additional treatments are often 
required in most patients2. Although they appear to 
be effective in attaining glycaemic control at fir st, 
sulfonylureas and oral hypoglycaemic agents are 
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difficult to tolerate in the long run due to their side 
effects3. Hence, patients with T2DM need new anti-
diabetic agents that are both effective and well 
tolerated, and can be used in combination with other 
available treatment options to improve overall 
glycaemic control, without the added risk of 
hypoglycaemia and weight gain. The sodium 
glucose co-transporter 2 (SGLT2) is located in the 
proximal tubule of the kidney and is responsible for 
approximately 90% reabsorption of the filtered 
glucose4. Due to maladaptive enhanced expression 
of SGLT2 in patients with T2DM, the capacity of 
the kidneys for reabsorption of glucose is increased, 
which further deteriorates hyperglycemia4. Sodium-
glucose co-transporter 2 inhibitors (SGLT2-I) form 
a new class of oral anti-diabetic drugs for the 
treatment of diabetes. They act by reducing renal 
glucose reabsorption and thus increasing urinary 
glucose excretion,5 resulting in reduced 
hyperglycaemia. SGLT2-I can be used as 
combination therapy with metformin, dipeptidyl 
peptidase 4 inhibitors (DPP-4), thiazolidinediones, 
sulfonylurea (SU) or other anti-diabetic agents, 
including insulin6-8. As their mechanism of action is 
independent of insulin, they can be used in 
appropriate candidates at any stage of diabetes. 
SGLT2-I is recommended as one of the second-line 
treatment options by the American Diabetes 
Association (ADA) and the European Association 
for the study of Diabetes (EASD)9. Empagliflozin is 
a potent sodium-glucose co-transporter-2 inhibitor 
utilized in the treatment of T2DM that has more 
than 2500-fold affinity for SGLT-2 over SGLT-110. 
This study was aimed to assess the efficacy and 
safety of two doses of empagliflozin (10 and 25 mg) 
when added to on-going dual oral anti-diabetic 
treatment (metformin plus sitagliptin) in patients 
with suboptimal glycaemic control. 
METHODOLOGY:
 
This study was conducted between January 2020 
and December 2020, at the department of Medicine, 
Naseer Teaching Hospital, Peshawar. Ethical 
approval was sought from the Institutional Review 
and Ethics Board of Naseer Teaching Hospital, 
Peshawar, which was provided. Consecutive 
patients who were previously diagnosed to have 
T2DM and did not achieve optimal glycaemic 
control (HbA1C of >7% and <12%) with Metformin 
2000 mg daily and Sitagliptin 100 mg daily were 
included in the study. Other inclusion criteria were 
age more than 18 years and both genders. Exclusion 
criteria were patients with impaired renal function 
(estimated Glomerular Filtration rate of <45ml/), 
pregnancy, chronic liver disease, cerebrovascular 
event or acute coronary syndrome. A total of 84 
patients met the inclusion criteria of which 7 were 
excluded as per the exclusion criteria and rest 
(seventy six) were included in the study. These were 
randomized to two groups of interventions by lottery 
method. Group A received empagliflozin 10 mg on 
top of the previous treatment and group B received 
empagliflozin 25 mg in addition to the previous 
treatment. Both the groups were followed up for 12 
weeks during the study duration of 1 year. Seven 
patients of group A and 10 patients of group B were 
lost to follow up. Therefore at the end of study 
duration had the follow up data of a total of 59 
patients (31 in group A and 28 in group B). Fasting 
blood glucose and HbA1c were obtained before and 
12 weeks after intervention with empagliflozin 
treatment. The SPSS 23.0 version was used to 
analyse the data. Mean±SD were calculated for 
quantitative variables like age, HbA1c and FBG. 
Percentages and frequency were calculated for 
qualitative variables like gender and presence of 
side effects. Analysis was done by doing paired 
sample t-tests to determine group mean differences 
between descriptive variables of the two 
intervention groups at 12 weeks and at baseline. To 
see the difference of outcome between the two 
intervention groups, an independent sample t-test 
was used. Side effects i.e. urinary tract infections 
and genital mycotic infections of both groups were 
compared to the baseline by using Fisher Exact t-
test. A value for p-value <0.05 was considered 
statistically significant. 
RESULTS: 
A total of 59 patients (29 males and 30 females) 
were included in the study. In Group A there were a 
total of 31 patients, out of which 13 patients were 
male and 18 were female, and the mean age was 
51.48±4.29 years. In Group B, there were a total of 
28 patients, out of which 16 patients were male and 
12 were female, and the mean age was 52.39±5.20 
years. The clinical and demographic variables of 
Group A     and      Group B    are    depicted     in  
Table 1 and 2, respectively. The  between  group 
difference is shown in Table 3. 
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Our study showed that the addition of either doses 
of empagliflozin as a further treatment option to 
T2DM patients having suboptimal glycaemic 
control already receiving Sitagliptin plus 
Metformin resulted in a significant HbA1c decline. 
Similar trend was also seen in the mean fasting 
plasma glucose (FPG) level decline after 12 weeks 
intervention in both the groups. This result of our 
study is in line with the results of numerous 
international studies6, 11-16. Recently, a study from 
Karachi has also demonstrated efficacy of 
empagliflozin in improvement of HbA1C levels in 
Pakistani population17. Unexpectedly, the in-
between group differences showed a higher HbA1C 
decline in empagliflozin 10 mg intervention group 
as compared to empagliflozin 25 mg group {-
1.43±0.79% vs -1.06±0.61 (p=0.047)}. This might 
be attributed to a high baseline HbA1C level in the 
empagliflozin 10 mg group. This contrasts with 
dose dependent decrease in HbA1C values as 
shown by Ferrannini et al18. Their study showed 
that after 12 weeks there was a 0.5 % decrease in 
the group receiving 10 mg while 0.6 % decrease in 
those receiving 25 mg of empagliflozin. However, 
there was no statistically significant difference in 
the mean FBG decline between both the groups. 
Both the doses of empagliflozin appeared quite 
safe. Although there was a numerically increased 
number of urinary tract infections (UTI) and genital 
mycotic infections in both the groups, these were 
 
Parameter Baseline Group A P-Value 
Age (Years) 51.48±4.29   
Gender (Male/Female, %) 13 (41.9%) / 18 (51.9%)   
Duration of Diabetes, Years (SD) 6.5±2.3   
HbA1C, % (SD) 10.11±0.79 8.67±1.03 0.000 
FPG, mg/dl (SD) 205.45±14.31 165.54±16.31 0.000 
UTI (%) 1 2 0.935 
Mycotic Infections (%) 1 3 0.893 
Table 2: Clinical and Demographic Data in Patients Receiving Empagliflozin Treatment in Group B 
*HbA1C=Glycated haemoglobin, FPG=Fasting plasma glucose, UTI=Urinary tract infections 
 
Table 3: Comparison of Pre and Post Added Empagliflozin Therapy Differences in Parameters Between Group A and Group B  
 
Parameter Baseline Group B P-Value 
Age (Years) 52.39±5.20   
Gender (Male/Female, %) 16 (57.1%) / 12 (42.9%)   
Duration of Diabetes, Years (SD) 6.8±2.5   
HbA1C, % (SD) 9.39±0.56 8.32±0.76 0.000 
FPG, mg/dl (SD) 215.39±20.17 175.82±20.48 0.000 
UTI (%) 1 2 0.929 
Mycotic Infections (%) 1 2 0.929 
Parameter Change from Baseline Treatment P-Value 
 Group A Group B  
Δ FPG, mg/dl (SD) -39.90±10.58 -39.57±12.46 0.91 
Δ HbA1C, % (SD) -1.43±0.79 -1.06±0.61 0.047 
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LIMITATIONS: 
A relatively small sample size and short duration of 
follow up are potential limitations of this study. 
CONCLUSION: 
Empagliflozin can be safely added to the oral anti-
diabetic regimen of patients with type-2 diabetes 
mellitus who have suboptimal glycaemic control 
and results in significant HbA1C reduction and a 
low side-effects rate. 
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